Corbus Pharmaceu Stock Price, News & Analysis

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference, scheduled for February 5-6, 2025, in New York. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat discussion led by analysts and conduct one-on-one meetings with investors.

The presentation is set for February 5, 2025, at 2:30 PM. The format will include both the fireside discussion and individual investor meetings, with a webcast link provided for virtual attendance.

Corbus Pharmaceuticals (NASDAQ: CRBP) announced that data from its first-in-human dose escalation clinical study of CRB-701 (SYS6002) will be presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. The study, conducted in the US and UK, focuses on a next-generation Nectin-4 targeting antibody-drug conjugate.

The Phase 1 study (NCT06265727) consists of three parts and evaluates safety, pharmacokinetics, and efficacy in patients with advanced solid tumors showing high Nectin-4 expression. Part A of the study examined four predetermined doses: 1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg, and 4.5 mg/kg Q3W. The study will continue with Part B (dose optimization) and Part C (dose expansion) to determine recommended doses and assess preliminary efficacy.

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco, CA. CEO Yuval Cohen, Ph.D., will deliver a presentation on January 16, 2025, at 11:15 a.m. PST and will be available for one-on-one investor meetings during the conference.

The prestigious healthcare conference is an invitation-only event, and interested parties are advised to contact their J.P. Morgan representative for attendance details.

Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated the Phase 1 clinical trial of CRB-601, dosing its first patient for the treatment of advanced solid tumors. CRB-601 is a monoclonal antibody targeting latent TGFβ activation by blocking the integrin αVβ8.

Pre-clinical data has shown that CRB-601 successfully overcomes tumor immune exclusion and enhances the effectiveness of immune checkpoint inhibitors in vivo. The study (NCT06603844) represents a significant step in evaluating CRB-601's potential in immunotherapy and its ability to modulate TGFβ signaling.

Corbus Pharmaceuticals announced that the FDA has granted Fast Track designation to CRB-701 for treating relapsed or refractory metastatic cervical cancer. CRB-701 is a next-generation antibody drug conjugate targeting Nectin-4, featuring a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE payload. The company has completed enrollment for the dose escalation portion of its Phase 1 clinical trial, which is evaluating safety, pharmacokinetics, and efficacy in patients with advanced solid tumors associated with high Nectin-4 expression. Initial data from the dose escalation study is expected in Q1 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the 7th Annual Evercore HealthCONx Conference, scheduled for December 3-5, 2024, in Coral Gables, FL. CEO Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event. The fireside chat is specifically scheduled for December 3, 2024, at 4:15 p.m. ET, with a webcast available for viewing.

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the upcoming Jefferies London Healthcare Conference, scheduled for November 19-21, 2024, in London, UK. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event. The fireside chat is specifically scheduled for November 19, 2024, at 10:30 a.m. GMT, with a webcast link provided for interested parties.

Corbus Pharmaceuticals reported Q3 2024 financial results and corporate updates. The company completed enrollment for the dose escalation part of its Phase 1 trial for CRB-701, with first data expected in Q1 2025. New pre-clinical data for CRB-913 was presented at Obesity Week 2024, with Phase 1 trial expected to start in Q1 2025. The company reported a net loss of $13.8 million, or $1.15 per share. Operating expenses increased to $15.5 million. Cash position stands at $159.4 million, expected to fund operations through Q3 2027. The company raised $35.6 million through ATM program and paid off an $11.8 million loan.

Corbus Pharmaceuticals (NASDAQ: CRBP) presented new pre-clinical data for CRB-913, its CB1 inverse agonist, at Obesity Week 2024. Key findings show CRB-913's brain levels are 15-fold lower than monlunabant, with a 10 times higher plasma-to-brain ratio. The compound demonstrated significant weight loss of up to 38% in DIO mice at doses ranging from 5 to 80 mg/kg/day. Notably, when replacing semaglutide treatment, CRB-913 maintained weight loss and doubled fat reduction compared to semaglutide maintenance. The company plans to begin Phase 1 clinical trials in Q1 2025.